We are a team of healthcare professionals around the world dedicated in helping other healthcare professionals, organizations, and patients in their medication options and drug regimens for the treatment of Hepatitis C. This includes medical consultations as well as delivery of your prescribed specialty medication to accomplish your treatment goals.
We deliver your medication, normally the next day, throughout to USA and to most international destinations via various shipping options. We also have the ability to have your prescription dispensed from one of our many pharmacy locations throughout the world.
We know Hep C is a serious health condition. We take our work very seriously and strive to bring you the best medications available from around the world that are approved by the USA, EU, and Canadian drug authorities.
We are respected providers of medications used for the treatment of Hepatitis C infection. We work closely with your health professional. We do not provide medical or health advice. Please consult your doctor if you have any question about any of the medicines you find in our site.
We offer all the latest treatments available for your Hep C infection. You can contact us to request a quote provided that you are already receiving medical attention and have a legitimate prescription. We will request your physician´s prescription before providing you with a formal quote.
The U.S. Food and Drug Administration today approved Technivie (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for the treatment of hepatitis C virus (HCV) genotype 4 infections in patients without scarring and poor liver function (cirrhosis).
Technivie in combination with ribavirin is the first drug that has demonstrated safety and efficacy to treat genotype 4 HCV infections without the need for co-administration of interferon, an FDA-approved drug also used to treat HCV infection.
“Today’s approval provides the first treatment option for patients with genotype 4 HCV infections without requiring use of interferon,” said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research.
The U.S. Food and Drug Administration (FDA) has approved AbbVie's (NYSE:ABBV) VIEKIRA PAK™, an all-oral, interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis. VIEKIRA PAK is the only FDA-approved regimen that contains three distinct mechanisms of action - NS5A inhibitor, NS3/4A protease inhibitor and a non-nucleoside NS5B polymerase inhibitor - that work together to attack the virus at three separate stages of the disease lifecycle to inhibit it from reproducing.
U.S. Food and Drug Administration (FDA) has recently approved Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg), the first once-daily single tablet regimen for the treatment of chronic hepatitis C genotype 1 infection in adults. Gilead reports that the majority of patients can be cured with a once-daily pill in a period of 8 to 12 weeks. Harvoni’s efficacy has been established in patients with chronic hepatitis C virus (HCV) genotype 1 infection.
U.S. Food and Drug Administration (FDA) has approved Sovaldi™ (sofosbuvir) 400 mg tablets, a once-daily oral nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen. Gilead states that it must be used with ribavirin or in combination with peginterferon alfa and ribavirin. However, physicians around the world have had success in combining sofosbuvir with other newly release antiviral medications such as Olysio (simeprevir).
OLYSIOTM (simeprevir) has been approved by the FDA in late 2013 and is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen with peginterferon-alfa and ribavirin (P/R), in HCV genotype 1 (G1) infected subjects with compensated liver disease (including cirrhosis). OLYSIOTM must not be used as monotherapy.
Hepcinat (Sofosbuvir) is a breakthrough treatment for Hepatitis C infections. Its mechanism of action involves inhibiting the enzyme which is necessary for the virus if it is to multiply. A complete cure may even be possible. Chronic hepatitis C is a serious infection of the liver which occurs following an infection with the hepatitis C virus. Upon reaching the cells of the liver, the virus begins to multiply, which it achieves by means of copying its DNA and RNA. This medicine is known as a nucleotide polymerase inhibitor, and it works directly on the virus itself. Hepcinat is made by NATCO in India under license by Gilead. Hepcinat contains the same active and inactive ingredients as Sovaldo except the film coating which does not affect its effectiveness.